Fanapt

Fanapt · pharmadog

Patent cliff

source: FDA Orange Book

first barrier falls

Apr 2, 2027

269 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (56)

Dec 28, 2031method-of-use (U-1674)US 9074254
Dec 28, 2031method-of-use (U-1674)US 9074254
Dec 28, 2031method-of-use (U-1674)US 9074254
Dec 28, 2031method-of-use (U-1674)US 9074254
Dec 28, 2031method-of-use (U-1674)US 9074254
Dec 28, 2031method-of-use (U-1674)US 9074254
Dec 28, 2031method-of-use (U-1674)US 9074254
Feb 10, 2031method-of-use (U-1674)US 90742564.6y
Feb 10, 2031method-of-use (U-1674)US 90742564.6y
Feb 10, 2031method-of-use (U-1674)US 90742564.6y
Feb 10, 2031method-of-use (U-1674)US 90742564.6y
Feb 10, 2031method-of-use (U-1674)US 90742564.6y
Feb 10, 2031method-of-use (U-1674)US 90742564.6y
Feb 10, 2031method-of-use (U-1674)US 90742564.6y
Jan 16, 2031method-of-use (U-1674)US 90727424.5y
Jan 16, 2031method-of-use (U-1674)US 90727424.5y
Jan 16, 2031method-of-use (U-1674)US 90727424.5y
Jan 16, 2031method-of-use (U-1674)US 90727424.5y
Jan 16, 2031method-of-use (U-1674)US 90727424.5y
Jan 16, 2031method-of-use (U-1674)US 90727424.5y
Jan 16, 2031method-of-use (U-1674)US 90727424.5y
Dec 17, 2030method-of-use (U-1674)US 90742554.4y
Dec 17, 2030method-of-use (U-1674)US 90742554.4y
Dec 17, 2030method-of-use (U-1674)US 90742554.4y
Dec 17, 2030method-of-use (U-1674)US 90742554.4y
Dec 17, 2030method-of-use (U-1674)US 90742554.4y
Dec 17, 2030method-of-use (U-1674)US 90742554.4y
Dec 17, 2030method-of-use (U-1674)US 90742554.4y
Oct 28, 2030method-of-use (U-1674)US 89996384.3y
Oct 28, 2030method-of-use (U-1674)US 89996384.3y
Oct 28, 2030method-of-use (U-1674)US 89996384.3y
Oct 28, 2030method-of-use (U-1674)US 89996384.3y
Oct 28, 2030method-of-use (U-1674)US 89996384.3y
Oct 28, 2030method-of-use (U-1674)US 89996384.3y
Oct 28, 2030method-of-use (U-1674)US 89996384.3y
Aug 31, 2030method-of-use (U-1685)US 86527764.2y
Aug 31, 2030method-of-use (U-1685)US 86527764.2y
Aug 31, 2030method-of-use (U-1685)US 86527764.2y
Aug 31, 2030method-of-use (U-1685)US 86527764.2y
Aug 31, 2030method-of-use (U-1685)US 86527764.2y
Aug 31, 2030method-of-use (U-1685)US 86527764.2y
Aug 31, 2030method-of-use (U-1685)US 86527764.2y
Apr 5, 2030method-of-use (U-1674)US 91571213.7y
Apr 5, 2030method-of-use (U-1674)US 91571213.7y
Apr 5, 2030method-of-use (U-1674)US 91571213.7y
Apr 5, 2030method-of-use (U-1674)US 91571213.7y
Apr 5, 2030method-of-use (U-1674)US 91571213.7y
Apr 5, 2030method-of-use (U-1674)US 91571213.7y
Apr 5, 2030method-of-use (U-1674)US 91571213.7y
Nov 2, 2027method-of-use (U-1625)US 85866101.3y
Nov 2, 2027method-of-use (U-1625)US 85866101.3y
Nov 2, 2027method-of-use (U-1625)US 85866101.3y
Nov 2, 2027method-of-use (U-1625)US 85866101.3y
Nov 2, 2027method-of-use (U-1625)US 85866101.3y
Nov 2, 2027method-of-use (U-1625)US 85866101.3y
Nov 2, 2027method-of-use (U-1625)US 85866101.3y

FDA exclusivities (7)

Apr 2, 2027I-939Indication (3y)269d
Apr 2, 2027I-939Indication (3y)269d
Apr 2, 2027I-939Indication (3y)269d
Apr 2, 2027I-939Indication (3y)269d
Apr 2, 2027I-939Indication (3y)269d
Apr 2, 2027I-939Indication (3y)269d

iloperidone

indications

all catalysts(0)

News(0)

comments(0)

Patent cliff

patents (56)

FDA exclusivities (7)

Report a data issue

Trials studying iloperidone